Quality-improvement guidelines for hepatic transarterial chemoembolization

CardioVascular and Interventional Radiology

Volumn 35, Issue 4, 2012, Pages 765-774

  Basile, Antonio ^a   Carrafiello, Gianpaolo ^b   Ierardi, Anna Maria ^b   Tsetis, Dimitrios ^c   Brountzos, Elias ^d  

^a GARIBALDI HOSPITAL   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; GEMCITABINE; IODINATED POPPYSEED OIL; IRINOTECAN; MICROSPHERE; MITOMYCIN C; OXALIPLATIN;

ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT DISEASE; BILOMA; BRAIN EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; COLORECTAL CARCINOMA; CONSERVATIVE TREATMENT; DECOMPENSATED LIVER CIRRHOSIS; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL HEMORRHAGE; HEPATIC ARTERY; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; LIVER ABSCESS; LIVER FAILURE; LIVER HEMORRHAGE; LIVER METASTASIS; LUNG EMBOLISM; OUTCOME ASSESSMENT; PAIN; PANCREATITIS; PATIENT ASSESSMENT; PLEURA EFFUSION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; THERAPY EFFECT; TOTAL QUALITY MANAGEMENT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VATER PAPILLA STENOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DIAGNOSTIC IMAGING; ETHIODIZED OIL; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT;

EID: 84866605572     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-012-0423-z     Document Type: Article

References (50)

1. Yamada R, Sato M, Kawabata M et al (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397-401 (Pubitemid 13073577)
2. Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolisation of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585-590
3. Pleguezuelo M, Marelli L, Misseri M et al (2008) TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev Anticancer Ther 8(10):1623-1641
4. Hong K, Khwaja A, Liapi E, et al. (2006) New intra-arterial drug delivery system for the treatment of liver cancer: Preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12(8):2563-2567
5. Kettenbach J, Stadler A, Katzler IV et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468-476
6. Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI), in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multiinstitutional study. Ann Surg Oncol 18(1): 192-198
7. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338
8. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35:519-524 (Pubitemid 34183954)
9. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917 (Pubitemid 37518510)
10. Bruix J, Sherman M (2005) Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42:1208-1236
11. Kothary N, Weintraub JL, Susman J, Rundback JH et al (2007) Transarterial chemoembolization for primary hepatocellular carcinomain patients at high risk. J Vasc Interv Radiol 18(12):1517-1526 (Pubitemid 350151875)
12. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ et al (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47(1):71-81 (Pubitemid 351171043)
13. Berger DH, Carrasco CH, Hohn DC et al (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: posttreatment management and complications. J Surg Oncol 60:116-121
14. Brown DB, Fundakowski CE, Lisker-Melman M et al (2004) Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 15:1209-1218 (Pubitemid 39487850)
15. Liapi E, Geschwind JFH (2011) Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 34:37-49
16. Ryan JM, Ryan BM, Smith TP (2004) Antibiotic prophylaxis in interventional radiology. J Vasc Interv Radiol 15:547-556 (Pubitemid 38758439)
17. Kim W, Clark TWI, Baum RA et al (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965-968 (Pubitemid 32756867)
18. Geschwind JF, Kaushik S, Ramsey DE et al (2002) Influence of a new prophylactic antibiotic therapy on the incidence of liver abscesses after chemoembolization treatment of liver tumors. J Vasc Interv Radiol 13:1163-1166 (Pubitemid 35332903)
19. Cheng HY, Shou Y, Wang X et al (2004) Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 10:2753-2755 (Pubitemid 39214518)
20. Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33-4033
21. Kim HC, Chung JW, Lee W (2005) Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 25:S25-S39 (Pubitemid 41686060)
22. Kwon JW, Chung JW, Song SY et al (2002) Transcatheter arterial chemoembolization for hepatocellular carcinomas in patients with celiac axis occlusion. J Vasc Interv Radiol 13(7):689-694 (Pubitemid 34793022)
23. Miyayama S, Yamashiro M, Okuda M et al (2009) Usefulness of cone-beam computed tomography during ultraselective transcatheter arterialchemoembolization for small hepatocellular carcinomas that cannot be showed on angiography. Cardiovasc Intervent Radiol 32(2):255-264
24. Takayasu K, Arii S, Matsuo N et al (2000) Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 175:699-704
25. Kubota K, Hisa N, Nishikawa T et al (2001) Evaluation of hepatocellular carcinoma after treatment with transcatheter arterial chemoembolization: comparison of lipiodol-CT, power Doppler sonography, and dynamic MRI. Abdom Imaging 26: 184-190 (Pubitemid 32187124)
26. Chopra S, Dodd GD, Chintapalli KN et al (2001) Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT. Am J Roentgenol 177:381-387 (Pubitemid 32660499)
27. Ernst O, Sergent G, Mizrahi D et al (1999) Treatment of hepatocellular carcinoma by transcatheter arterial chemo-embolization: comparison of planned periodic chemo-embolization and chemo-embolization based on tumor response. Am J Roentgenol 172:59-64 (Pubitemid 29028431)
28. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1): 52-60
29. Oliveri RA, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 16:CD004787
30. Ray CE, Haskal ZJ, Geschwind GFH et al (2011) The Use of transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a response to the Cochrane Collaboration Review of 2011. J Vasc Interv Radiol 22:1693-1696
31. Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359(9319):1734-1739 (Pubitemid 34607087)
32. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171 (Pubitemid 34454013)
33. Llovet JM, Bruix J, for the Barcelona-Clinic Liver Cancer Group (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolisation improves survival. Hepatology 37:429-442 (Pubitemid 36152543)
34. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 30:6-25 (Pubitemid 44900485)
35. Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41-52
36. Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicineluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541-551
37. Tellez C, Benson AB III, Lyster MT et al (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82: 1250-1259 (Pubitemid 28155386)
38. Vogl TJ, Gruber T, Balzer JO et al (2009) Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 250(1):281-289
39. Aliberti C, Tilli M, Benea G et al (2006) Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: Preliminary results. Anticancer Res 26(5B):3793-3795 (Pubitemid 44701461)
40. Fiorentini G, Aliberti C, Turrisi G et al (2007) Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 21(6):1085-1091
41. Roche A, Girish BV, de Baère T et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 3(1):136-140 (Pubitemid 36790502)
42. de Baere T, Deschamps F, Teriitheau C et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19:855-861
43. Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16: 353-361 (Pubitemid 40354852)
44. Gusani NJ, Balaa FK, Steel JL et al (2008) Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12(1):129-137
45. Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 31(5):883-888
46. Poggi G, Amatu A, Montagna B et al (2009) OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 32(6):1187-1192
47. Brown DB, Cardella JF, Sacks D et al (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20:S219-S226
48. Sueyoshi E, Hayashida T, Sakamoto I et al (2010) Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 195:245-251
49. Chan AO, Yuen MF, Hui CK, et al. (2002) A prospective study regarding the complications of transcatheter intra-arterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94(6):1747-1752 (Pubitemid 34241113)
50. Group d'Etude et de Treatment du Carcinoma Hepatocellulaire (1995) A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261